NCT05143970 2024-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Unknown
Clinical Trials
75 trialsNCT04309578 2024-02-28
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Unknown
NCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
NCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown
NCT06130007 2023-11-13
B2023-153
Sun Yat-sen University
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05912062 2023-09-29
BiOnHER
Institut Català d'Oncologia
Unknown
NCT02679040 2023-07-03
HIST-RIC
Institut Paoli-Calmettes
Phase 2 Unknown
NCT00431704 2023-03-24
VinCaT
National Cancer Institute, Naples
Phase 2 Unknown
NCT05656079 2022-12-19
easy laugh
Shanghai Pudong Hospital
Phase NA Unknown
NCT03907800 2022-10-27
NeoPATH
Ruijin Hospital
Phase 2 Unknown
NCT05577442 2022-10-19
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT04917900 2022-10-10
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
West China Hospital
Phase 2 Unknown
NCT05170256 2022-08-12
HERES
Rigshospitalet, Denmark
Phase 2 Unknown
NCT05483439 2022-08-05
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Phase 2 Unknown
NCT05429294 2022-06-23
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT03913234 2022-05-10
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Yonsei University
Phase 1/2 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT05346861 2022-04-26
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
Phase 3 Unknown
NCT05311189 2022-04-05
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05030519 2022-03-02
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Zhejiang Cancer Hospital
Unknown
NCT05193292 2022-01-14
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT05189067 2022-01-12
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT05177666 2022-01-04
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
The University of Hong Kong-Shenzhen Hospital
Unknown
NCT03238495 2021-12-07
HERMET
University of Kansas Medical Center
Phase 2 Unknown
NCT05076695 2021-10-13
NeoTPPF
Fudan University
Phase 2 Unknown
NCT04380012 2021-07-15
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04962425 2021-07-15
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Peking University Third Hospital
Unknown
NCT04960943 2021-07-14
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Fudan University
Phase 2 Unknown
NCT04961307 2021-07-14
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Peking University Third Hospital
Unknown
NCT04760431 2021-06-02
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04900311 2021-05-25
Pyramid
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT01359397 2021-01-27
B-DOCT
The Netherlands Cancer Institute
Phase 2 Unknown
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT04609540 2020-12-16
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Shandong Cancer Hospital and Institute
Unknown
NCT04639271 2020-11-20
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT03367676 2020-03-10
SOBER
Ruijin Hospital
Phase 2 Unknown
NCT04246502 2020-02-05
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT03994107 2020-01-22
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Peking Union Medical College
Phase 1/2 Unknown
NCT04152057 2019-11-05
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
West China Hospital
Phase 1/2 Unknown
NCT03756064 2019-08-13
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
Phase NA Unknown
NCT04034823 2019-07-26
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT03185988 2019-07-19
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
Phase 2 Unknown
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT03910712 2019-04-10
Pyrotinib
Peking Union Medical College Hospital
Phase 2 Unknown